Back to Search
DAVID REARDON, MD
MD
Anatomic Pathology & Clinical Pathology Physician
NPI: 1871572651Individual
Specialties, Licenses & Credentials
Pathology — Anatomic Pathology & Clinical Pathology
Code: 207ZP0102X
ME50460(FL)
Pathology — Blood Banking & Transfusion Medicine
Code: 207ZB0001X
ME50460(FL)
Research & Publications (20)
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
PMID 19562254·J Neurooncol·2010
3-trial
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
PMID 19514083·Cancer·2009
8-other
Will integrin inhibitors have proangiogenic effects in the clinic?
PMID 19584855·Nat Med·2009
7-preclinical
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
PMID 19248046·Cancer·2009
3-trial
Targeting multiple kinases in glioblastoma multiforme.
PMID 19243279·Expert Opin Investig Drugs·2009
6-review
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
PMID 19533023·J Neurooncol·2009
3-trial
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
PMID 19402172·Cancer·2009
3-trial
Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing.
PMID 19212703·J Neurooncol·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1620 MEDICAL LN, SUITE 100
FT MYERS, FL 33907 - Phone
- (239) 275-1164
Quick Facts
- NPI
- 1871572651
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile